Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival
ABSTRACT Purpose Recent research (Li et al. 2021) suggests an upregulated expression and activation of H1 receptors on macrophages in the tumor microenvironment, and concomitant H1‐antihistamine use is associated with improved overall survival in patients with lung and skin cancers receiving immunot...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cancer Medicine |
| Online Access: | https://doi.org/10.1002/cam4.70583 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841543417061965824 |
|---|---|
| author | Yin Leung Terry Cheuk‐Fung Yip Grace Lai‐Hung Wong Vincent Wai‐Sun Wong Vicki Wing‐Ki Hui Tony Shu‐Kam Mok Henry Lik‐Yuen Chan Stephen Lam Chan Rashid Nok‐Shun Lui |
| author_facet | Yin Leung Terry Cheuk‐Fung Yip Grace Lai‐Hung Wong Vincent Wai‐Sun Wong Vicki Wing‐Ki Hui Tony Shu‐Kam Mok Henry Lik‐Yuen Chan Stephen Lam Chan Rashid Nok‐Shun Lui |
| author_sort | Yin Leung |
| collection | DOAJ |
| description | ABSTRACT Purpose Recent research (Li et al. 2021) suggests an upregulated expression and activation of H1 receptors on macrophages in the tumor microenvironment, and concomitant H1‐antihistamine use is associated with improved overall survival in patients with lung and skin cancers receiving immunotherapy. Therefore, we retrospectively evaluated the impacts of H1‐antihistamine use in cancer patients during immunotherapy. Methods All patients who had received at least one dose of immune checkpoint inhibitors (ICIs) from July 1, 2014 to October 31, 2019 were identified from Hong Kong's territory‐wide database, with this date defined as the baseline. A 1‐month landmark analysis was conducted with follow–for up to 6 months, including an exposure period of 1 month before and after the baseline date. Patients were grouped according to the types of primary cancer and the percentages of daily H1‐antihistamine usage within the exposure period. The primary outcome was overall survival. Results A total of 1740 (65.1% male, mean age 61.9 years) were included in the landmark analysis, of which 529 (30.4%) and 307 (17.6%) had primary lung and liver malignancies. The multivariable Cox regression model estimated statistically significant improvement in overall survival of intermediate use in patients with primary lung malignancies (adjusted hazard ratio [aHR] 0.223, 95% confidence interval [CI] 0.052–0.958, p = 0.044), but not with primary liver maligancies. Similar frequency‐dependent effects were identified in Kaplan–Meier analysis. Conclusion The benefits of adjunctive use of H1‐antihistamines may be generation‐ and tumor‐dependent. Further clinical and mechanistic studies are required to confirm the findings. |
| format | Article |
| id | doaj-art-a6b91278d4a54619a53756a110dbb00d |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-a6b91278d4a54619a53756a110dbb00d2025-01-13T13:22:39ZengWileyCancer Medicine2045-76342025-01-01141n/an/a10.1002/cam4.70583Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient SurvivalYin Leung0Terry Cheuk‐Fung Yip1Grace Lai‐Hung Wong2Vincent Wai‐Sun Wong3Vicki Wing‐Ki Hui4Tony Shu‐Kam Mok5Henry Lik‐Yuen Chan6Stephen Lam Chan7Rashid Nok‐Shun Lui8Medical Data Analytics Centre The Chinese University of Hong Kong Hong Kong SAR ChinaMedical Data Analytics Centre The Chinese University of Hong Kong Hong Kong SAR ChinaMedical Data Analytics Centre The Chinese University of Hong Kong Hong Kong SAR ChinaMedical Data Analytics Centre The Chinese University of Hong Kong Hong Kong SAR ChinaMedical Data Analytics Centre The Chinese University of Hong Kong Hong Kong SAR ChinaState Key Laboratory of Translational Oncology, Department of Clinical Oncology The Chinese University of Hong Kong Hong Kong SAR ChinaMedical Data Analytics Centre The Chinese University of Hong Kong Hong Kong SAR ChinaState Key Laboratory of Translational Oncology, Department of Clinical Oncology The Chinese University of Hong Kong Hong Kong SAR ChinaMedical Data Analytics Centre The Chinese University of Hong Kong Hong Kong SAR ChinaABSTRACT Purpose Recent research (Li et al. 2021) suggests an upregulated expression and activation of H1 receptors on macrophages in the tumor microenvironment, and concomitant H1‐antihistamine use is associated with improved overall survival in patients with lung and skin cancers receiving immunotherapy. Therefore, we retrospectively evaluated the impacts of H1‐antihistamine use in cancer patients during immunotherapy. Methods All patients who had received at least one dose of immune checkpoint inhibitors (ICIs) from July 1, 2014 to October 31, 2019 were identified from Hong Kong's territory‐wide database, with this date defined as the baseline. A 1‐month landmark analysis was conducted with follow–for up to 6 months, including an exposure period of 1 month before and after the baseline date. Patients were grouped according to the types of primary cancer and the percentages of daily H1‐antihistamine usage within the exposure period. The primary outcome was overall survival. Results A total of 1740 (65.1% male, mean age 61.9 years) were included in the landmark analysis, of which 529 (30.4%) and 307 (17.6%) had primary lung and liver malignancies. The multivariable Cox regression model estimated statistically significant improvement in overall survival of intermediate use in patients with primary lung malignancies (adjusted hazard ratio [aHR] 0.223, 95% confidence interval [CI] 0.052–0.958, p = 0.044), but not with primary liver maligancies. Similar frequency‐dependent effects were identified in Kaplan–Meier analysis. Conclusion The benefits of adjunctive use of H1‐antihistamines may be generation‐ and tumor‐dependent. Further clinical and mechanistic studies are required to confirm the findings.https://doi.org/10.1002/cam4.70583 |
| spellingShingle | Yin Leung Terry Cheuk‐Fung Yip Grace Lai‐Hung Wong Vincent Wai‐Sun Wong Vicki Wing‐Ki Hui Tony Shu‐Kam Mok Henry Lik‐Yuen Chan Stephen Lam Chan Rashid Nok‐Shun Lui Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival Cancer Medicine |
| title | Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival |
| title_full | Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival |
| title_fullStr | Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival |
| title_full_unstemmed | Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival |
| title_short | Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival |
| title_sort | concomitant usage of h1 antihistamines and immune checkpoint inhibitors on cancer patient survival |
| url | https://doi.org/10.1002/cam4.70583 |
| work_keys_str_mv | AT yinleung concomitantusageofh1antihistaminesandimmunecheckpointinhibitorsoncancerpatientsurvival AT terrycheukfungyip concomitantusageofh1antihistaminesandimmunecheckpointinhibitorsoncancerpatientsurvival AT gracelaihungwong concomitantusageofh1antihistaminesandimmunecheckpointinhibitorsoncancerpatientsurvival AT vincentwaisunwong concomitantusageofh1antihistaminesandimmunecheckpointinhibitorsoncancerpatientsurvival AT vickiwingkihui concomitantusageofh1antihistaminesandimmunecheckpointinhibitorsoncancerpatientsurvival AT tonyshukammok concomitantusageofh1antihistaminesandimmunecheckpointinhibitorsoncancerpatientsurvival AT henrylikyuenchan concomitantusageofh1antihistaminesandimmunecheckpointinhibitorsoncancerpatientsurvival AT stephenlamchan concomitantusageofh1antihistaminesandimmunecheckpointinhibitorsoncancerpatientsurvival AT rashidnokshunlui concomitantusageofh1antihistaminesandimmunecheckpointinhibitorsoncancerpatientsurvival |